Potassium Channel Kv1.3 Is Highly Expressed by Microglia in Human Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
Recent genetic studies suggest a central role for innate immunity in Alzheimer's disease (AD) pathogenesis, wherein microglia orchestrate neuroinflammation. Kv1.3, a voltage-gated potassium channel of therapeutic relevance in autoimmunity, is upregulated by activated microglia and mediates amyloid-mediated microglial priming and reactive oxygen species production in vitro. We hypothesized that Kv1.3 channel expression is increased in human AD brain tissue. In a blinded postmortem immunohistochemical semi-quantitative analysis performed on ten AD patients and ten non-disease controls, we observed a significantly higher Kv1.3 staining intensity (p = 0.03) and Kv1.3-positive cell density (p = 0.03) in the frontal cortex of AD brains, compared to controls. This paralleled an increased number of Iba1-positive microglia in AD brains. Kv1.3-positive cells had microglial morphology and were associated with amyloid-β plaques. In immunofluorescence studies, Kv1.3 channels co-localized primarily with Iba1 but not with astrocyte marker GFAP, confirming that elevated Kv1.3 expression is limited to microglia. Higher Kv1.3 expression in AD brains was also confirmed by western blot analysis. Our findings support that Kv1.3 channels are biologically relevant and microglia-specific targets in human AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Kv1.3 channels are highly expressed by pro-inflammatory microglia in mouse models of refractory seizures as well as radiation neurotoxicity and recently, Kv1.3 blockade by Pap1 was shown to have amyloid-lowering and neuroprotective effects in AD mouse models [26, 48, 49, 51, 62, 63].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [48]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Kv1.3 channels are highly expressed by pro-inflammatory microglia in mouse models of refractory seizures as well as radiation neurotoxicity and recently, Kv1.3 blockade by Pap1 was shown to have amyloid-lowering and neuroprotective effects in AD mouse models [26, 48, 49, 51, 62, 63].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Kv1.3 channels were also highly upregulated by CD11b+CD45high CNS immune cells in the 5xFAD brain, consistent with previous findings of increased Kv1.3 expression in microglia in human AD [48].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [48]
The cited source says what the claim attributes to it.
In the citing paper
“Higher Iba1 was noted in the AD frontal cortex in four studies,20, 63, 64, 68 but was the same as control in three others32, 70, 74 and lower in the white matter of the frontal lobe in one study.32”
From Markers of microglia in post-mortem brain samples from patients with Alzheimer’s disease: a systematic review (2018) · cites this paper as [63]
In the citing paper
“and are highly expressed by microglia surrounding Aβ plaques in AD [48].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 1×
“The central role of microglia in AD pathogenesis is further supported by genetic studies that identified an AD susceptibility locus in CD33, and an increased risk of AD associated with allelic variants in Triggering Receptor Expressed on Myeloid cells-2 (TREM2), both microglial proteins [4–6].”
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“[15] confers an increased risk for late-onset AD [4].”
BackgroundSelf-citationMicroglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · cited 1×
“It is suggested that early microglial activation in AD has a neuroprotective effect by promoting clearance of amyloid-β (Aβ, however, in the later stages pro-inflammatory cytokines produced by activated microglia have detrimental effects that promote neurodegeneration [3].”
BackgroundA Meta-Analysis of Cytokines in Alzheimer's Disease
Swardfager, W., Lanctôt, K., Rothenburg, L., Wong, A., Cappell, J., & Herrmann, N. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.012 · Cited by 1,108
Microglial cell origin and phenotypes in health and disease
Saijo, K., & Glass, C. K. (2011) · Nature Reviews Immunology · doi:10.1038/nri3086 · Cited by 1,100 · cited 3×
“The mechanisms underlying microglial polarity (pro-inflammatory M1 or anti-inflammatory or neuroprotective M2) are being defined and it is possible that altered expression of potassium channels could characterize these microglial states [17, 33].”
BackgroundAlzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.014 · Cited by 1,004
Heterogeneity of Microglial Activation in the Innate Immune Response in the Brain
Colton, C. A. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9164-4 · Cited by 877
Grissmer, S., Nguyen, A. N., Aiyar, J., Hanson, D. C., Mather, R. J., Gutman, G. A., Karmilowicz, M. J., Auperin, D. D., & Chandy, K. G. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10594-4 · Cited by 777
Cited by
Hopperton, K. E., Mohammad, D., Trépanier, M. O., Giuliano, V, & Bazinet, R. P. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.246 · Cited by 622
Rangaraju, S., Dammer, E. B., Raza, S. A., Rathakrishnan, P., Xiao, H., Gao, T., Duong, D. M., Pennington, M. W., Lah, J. J., Seyfried, N. T., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0254-8 · Cited by 430
Self-citationNguyen, H. M., Grössinger, E. M., Horiuchi, M., Davis, K. W., Jin, L., Maezawa, I., & Wulff, H. (2017) · Glia · doi:10.1002/glia.23078 · Cited by 178
Self-citationLau, V., Ramer, L., & Tremblay, M.-È. (2023) · Nature Communications · doi:10.1038/s41467-023-37304-3 · Cited by 167
Rangaraju, S., Dammer, E. B., Raza, S. A., Gao, T., Xiao, H., Betarbet, R., Duong, D. M., Webster, J. A., Hales, C. M., Lah, J. J., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0266-4 · Cited by 136
Self-citationHow to reprogram microglia toward beneficial functions
Fumagalli, M., Lombardi, M., Gressens, P., & Verderio, C. (2018) · Glia · doi:10.1002/glia.23484 · Cited by 133
Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson’s disease
Sarkar, S., Nguyen, H. M., Malovic, E., Luo, J. D., Langley, M. R., Palanisamy, B. N., Singh, N., Manne, S., Neal, M. P., Gabrielle, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci136174 · Cited by 139
Self-citationMaezawa, I., Nguyen, H. M., Di Lucente, J., Jenkins, D. P., Singh, V., Hilt, S., Kim, K., Rangaraju, S., Levey, A. I., Wulff, H., et al. (2018) · Brain · doi:10.1093/brain/awx346 · Cited by 125
“3 is typically expressed highest in microglia in the brain (Rangaraju et al., 2015).”
BackgroundMethodInfluentialSelf-citationUse of Peptides for the Management of Alzheimer’s Disease: Diagnosis and Inhibition
Baig, M. H., Ahmad, K., Rabbani, G., & Choi, I. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00021 · Cited by 104
The secret life of ion channels: Kv1.3 potassium channels and proliferation
Pérez-García, M. T., Cidad, P., & López‐López, J. R. (2017) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00136.2017 · Cited by 114
Pérez-Verdaguer, M., Capera, J., Serrano‐Novillo, C., Estadella, I., Sastre, D., & Felipe, A. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1112792 · Cited by 113
Feng, L., Murugan, M., Bosco, D. B., Liu, Y., Peng, J., Worrell, G. A., Wang, H., Ta, L. E., Richardson, J. R., Shen, Y., et al. (2019) · Glia · doi:10.1002/glia.23616 · Cited by 110
Wang, X., Li, G., Guo, J., Zhang, Z., Zhang, S., Zhu, Y., Cheng, J., Yu, L., Ji, Y., & Tao, J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01393 · Cited by 105
Plescher, M., Seifert, G., Hansen, J. N., Bedner, P., Steinhäuser, C., & Halle, A. (2018) · Glia · doi:10.1002/glia.23318 · Cited by 100
Di Lucente, J., Nguyen, H. M., Wulff, H., Jin, L., & Maezawa, I. (2018) · Glia · doi:10.1002/glia.23457 · Cited by 96
Self-citationVenom-derived peptide inhibitors of voltage-gated potassium channels
Norton, R. S., & Chandy, K. G. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.002 · Cited by 92
Ion channels and transporters in microglial function in physiology and brain diseases
Luo, L., Song, S., Ezenwukwa, C. C., Jalali, S., Sun, B., & Sun, D. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104925 · Cited by 85
Rangaraju, S., Raza, S. A., Pennati, A., Deng, Q., Dammer, E. B., Duong, D., Pennington, M. W., Tansey, M. G., Lah, J. J., Betarbet, R., et al. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0906-6 · Cited by 75
“3 channels are highly expressed by microglia in the brains of AD patients as compared to non-AD controls [7].”
BackgroundMethodSelf-citationKou, K. G. M., Pflueger, J. J., Kiho, T., Morrill, L. C., Fisher, E. L., Clagg, K., Lebold, T. P., Kisunzu, J. K., & Sarpong, R. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b05043 · Cited by 72
Inhibition of the potassium channel Kv1.3 reduces infarction and inflammation in ischemic stroke
Chen, Y., Nguyen, H. M., Maezawa, I., Jin, L., & Wulff, H. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.513 · Cited by 70
Self-citationBeyond Amyloid and Tau: The Critical Role of Microglia in Alzheimer’s Disease Therapeutics
Dias, D., & Socodato, R. (2025) · Biomedicines · doi:10.3390/biomedicines13020279 · Cited by 70
Stebbing, M. J., Cottee, J. M., & Rana, I. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00497 · Cited by 61
The voltage-gated potassium channel KV1.3 as a therapeutic target for venom-derived peptides
Tajti, G., Wai, D. C. C., Panyi, G., & Norton, R. S. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114146 · Cited by 65
Potassium channel expression and function in microglia: Plasticity and possible species variations
Nguyen, H. M., Blomster, L. V., Christophersen, P., & Wulff, H. (2017) · Channels · doi:10.1080/19336950.2017.1300738 · Cited by 61
Mitochondrial K+ channels and their implications for disease mechanisms
Checchetto, V., Leanza, L., Stefani, D. D., Rizzuto, R., Gulbins, E., & Szabó, I. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107874 · Cited by 59
A New Hypothesis for Alzheimer’s Disease: The Lipid Invasion Model
Rudge, J. D. (2022) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-210299 · Cited by 58
Nguyen, H. M., di Lucente, J., Chen, Y., Cui, Y., Ibrahim, R. H., Pennington, M. W., Jin, L., Maezawa, I., & Wulff, H. (2020) · Glia · doi:10.1002/glia.23847 · Cited by 54
Self-citationRamesha, S., Rayaprolu, S., Bowen, C. A., Giver, C. R., Bitarafan, S., Nguyen, H. M., Gao, T., Chen, M. J., Nwabueze, N. V., Dammer, E. B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013545118 · Cited by 52
Self-citationPike, A. F., Szabó, I., Veerhuis, R., & Bubacco, L. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00293-z · Cited by 52
Liao, Q., Feng, Y., Yang, B., & Lee, S. M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.08.011 · Cited by 50
Charolidi, N., Schilling, T., & Eder, C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128463 · Cited by 44
Chen, X., Feng, Y., Quinn, R. J., Pountney, D. L., Richardson, D. R., Mellick, G. D., & Ma, L. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000743 · Cited by 45
Villa, C., Suphesiz, H., Combi, R., & Akyüz, E. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.111197 · Cited by 42
Kv1.3 inhibition attenuates neuroinflammation through disruption of microglial calcium signaling
Fomina, A. F., Nguyen, H. M., & Wulff, H. (2020) · Channels · doi:10.1080/19336950.2020.1853943 · Cited by 42
Microglia in Alzheimer's Disease: A Role for Ion Channels
Thei, L., Imm, J., Kaisis, E., Dallas, M. L., & Kerrigan, T. L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00676 · Cited by 36
Maqoud, F., Scala, R., Hoxha, M., Zappacosta, B., & Tricarico, D. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210119095626 · Cited by 40
Yuan, X., Han, S., Manyande, A., Gao, F., Wang, J., Zhang, W., & Tian, X. (2022) · European Journal of Pain · doi:10.1002/ejp.2059 · Cited by 37
Brooks, L. R. K., & Mias, G. I. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00392 · Cited by 32
Pharmacological blockade of KV1.3 channel as a promising treatment in autoimmune diseases
Cañas, C. A., Castaño-Valencia, S., & Castro‐Herrera, F. (2022) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2022.100146 · Cited by 32
Vay, S. U., Flitsch, L. J., Rabenstein, M., Monière, H., Jakovčevski, I., Anđjus, P. R., Bijelić, D. D., Blaschke, S. J., Walter, H. L., Fink, G. R., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01779-4 · Cited by 31
Roles of Microglial Ion Channel in Neurodegenerative Diseases
Cojocaru, A., Burada, E., Bălșeanu, A.-T., Deftu, A., Cătălin, B., Popa‐Wagner, A., & Osiac, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061239 · Cited by 32
The Kv1.3 K+ channel in the immune system and its “precision pharmacology” using peptide toxins
Varga, Z., Tajti, G., & Panyi, G. (2021) · Biologia Futura · doi:10.1007/s42977-021-00071-7 · Cited by 30
Bozic, I. D., Tesovic, K., Laketa, D., Adžić, M., Jakovljevic, M., Bjelobaba, I. M., Savić, D. Z., Nedeljković, N., Peković, S., & Lavrnja, I. C. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2509-8 · Cited by 30
Wenzel, T. J., Desjarlais, J. D., & Mousseau, D. D. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03876-0 · Cited by 29
Modulators of microglia: a patent review
Papa, S., Caron, I., Rossi, F., & Veglianese, P. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1135901 · Cited by 29
Microglial ion channels: Key players in non-cell autonomous neurodegeneration
Sarkar, S. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105861 · Cited by 29
The role of microglia membrane potential in chemotaxis
Laprell, L., Schulze, C., Brehme, M.-L., & Oertner, T. G. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02048-0 · Cited by 29
Wu, W., An, X., Gong, W., Yang, L., Liu, N., Liu, B., Guo, B., Jiang, Q. Y., & Li, L. (2024) · Advanced Science · doi:10.1002/advs.202406822 · Cited by 27
Kv1.3 in the spotlight for treating immune diseases
Navarro‐Pérez, M., Capera, J., Benavente-Garcia, A., Cassinelli, S., Colomer-Molera, M., & Felipe, A. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2315021 · Cited by 27
Microglia in Alzheimer’s Disease
Süß, P., & Schlachetzki, J. C. M. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200212155234 · Cited by 28
Proximity Labeling Proteomics Reveals Kv1.3 Potassium Channel Immune Interactors in Microglia
Bowen, C. A., Nguyen, H. M., Lin, Y. Q., Bagchi, P., Natu, A., Espinosa‐García, C., Werner, E., Kumari, R., Brandelli, A. D., Kumar, P., et al. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100809 · Cited by 25
Self-citationGurram, P. C., Satarker, S., & Nampoothiri, M. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150597 · Cited by 25
Gao, T., Raza, S. A., Ramesha, S., Nwabueze, N. V., Tomkins, A. J., Cheng, L., Xiao, H., Yepes, M., & Rangaraju, S. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1510-8 · Cited by 25
Self-citationRevuelta, M., Urrutia, J., Villarroel, Á., & Casis, Ó. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.868842 · Cited by 25
Kv1.3 K + Channel Physiology Assessed by Genetic and Pharmacological Modulation
Varanita, T., Angi, B., Scattolini, V., & Szabó, I. (2022) · Physiology · doi:10.1152/physiol.00010.2022 · Cited by 24
Ohgomori, T., Yamasaki, R., Takeuchi, H., Kadomatsu, K., Kira, J., & Jinno, S. (2017) · European Journal of Neuroscience · doi:10.1111/ejn.13650 · Cited by 24
The NLRP3 Inflammasome in the Pathogenesis and Treatment of Alzheimer’s Disease
Golzari-Sorkheh, M., Brown, C. E., Weaver, D. F., & Reed, M. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210660 · Cited by 23
Yan, W., Zhang, M., Yu, Y., Yi, X., Guo, T., Hu, H., Sun, Q., Chen, M., Xiong, H., & Chen, L. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.112988 · Cited by 22
Liu, X., Wang, H., Tian, X., Luo, Y., Ma, M., Zheng, Z., Wang, Y., Feng, S., Wang, Q., Xu, Z. F., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03488-2 · Cited by 21
Gallium-68-labeled radiopharmaceuticals: a review
Tanwar, K. S., & Pandey, M. K. (2025) · Chemical Society Reviews · doi:10.1039/d5cs00392j · Cited by 21
Targeting Kv1.3 channels to reduce white matter pathology after traumatic brain injury
Reeves, T. M., Trimmer, P. A., Colley, B. S., & Phillips, L. L. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.06.011 · Cited by 21
Biochemical and physiological properties of K+ channel-associated AKR6A (Kvβ) proteins
Raph, S. M., Bhatnagar, A., & Nystoriak, M. A. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.03.023 · Cited by 21
Microglial Potassium Channels: From Homeostasis to Neurodegeneration
Cocozza, G., Garofalo, S., Capitani, R., D’Alessandro, G., & Limatola, C. (2021) · Biomolecules · doi:10.3390/biom11121774 · Cited by 20
Yuan, J. X., Bafakih, F. F., Mandell, J. W., Horton, B. J., & Munson, J. M. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw090 · Cited by 20
Endothelial Degeneration of Parkinson's Disease is Related to Alpha-Synuclein Aggregation
Yang, P., Min, X., Mohammadi, M., Turner, C. P., Faull, R. L. M., Waldvogel, H. J., Dragunow, M., & Guan, J. (2017) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000370 · Cited by 20
Role of Ion Channels in Alzheimer’s Disease Pathophysiology
Bhoi, R., Mitra, T., Tejaswi, K., Manoj, V., & Ghatak, S. (2025) · The Journal of Membrane Biology · doi:10.1007/s00232-025-00341-8 · Cited by 19
“3 channels, especially close to amyloid plaques, which mediate amyloid-induced priming and Reactive oxygen species (ROS) production (Schilling et al. 2000; Rangaraju et al. 2015).”
Alonso, E., Vieira, A. C., Rodríguez, I., Alvariño, R., Gegunde, S., Fuwa, H., Suga, Y., Sasaki, M., Alfonso, A., Cifuentes, J. M., et al. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00012 · Cited by 19
Nicolazzo, J. A., Pan, Y., Stefano, I. D., Choy, K. H. C., Reddiar, S. B., Low, Y. L., Wai, D. C. C., Norton, R. S., & Jin, L. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.11.003 · Cited by 19
Self-citationMINCR: A long non-coding RNA shared between cancer and neurodegeneration
Pandini, C., Garofalo, M., Rey, F., Garau, J., Zucca, S., Sproviero, D., Bordoni, M., Berzero, G., Davin, A., Poloni, T. E., et al. (2021) · Genomics · doi:10.1016/j.ygeno.2021.10.008 · Cited by 18
Why do platelets express K+ channels?
Wright, J. R., & Mahaut‐Smith, M. P. (2021) · Platelets · doi:10.1080/09537104.2021.1904135 · Cited by 16
Lee, H., Lee, Y., Chung, C., Park, S., Shin, H. J., Joe, E.-H., Lee, S. J., Kim, D. W., Jo, S., & Choi, S. (2024) · Glia · doi:10.1002/glia.24629 · Cited by 15
Functional Potassium Channels in Macrophages
Man, Q., Gao, Z., & Chen, K. (2023) · The Journal of Membrane Biology · doi:10.1007/s00232-022-00276-4 · Cited by 15
Otuyemi, B. A., Jackson, T., Ma, R., Monteiro, A. R., Seifi, M., & Swinny, J. D. (2023) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2023.102233 · Cited by 13
Pan, Y., Kagawa, Y., Sun, J., Lucas, D. D., Takechi, R., Mamo, J. C. L., Wai, D. C. C., Norton, R. S., Jin, L., & Nicolazzo, J. A. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01387-z · Cited by 12
Self-citationReddiar, S. B., Jin, L., Wai, D. C. C., Csóti, A., Panyi, G., Norton, R. S., & Nicolazzo, J. A. (2021) · Toxicon · doi:10.1016/j.toxicon.2021.03.002 · Cited by 12
Self-citationReddiar, S. B., de Veer, M., Paterson, B. M., Sepehrizadeh, T., Wai, D. C. C., Csóti, A., Panyi, G., Nicolazzo, J. A., & Norton, R. S. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00614 · Cited by 12
Huang, I. Y., Hsu, Y.-L., Chen, C., Chen, M.-F., Wen, Z., Huang, H.-T., & Liu, I. Y. (2018) · Marine Drugs · doi:10.3390/md16110405 · Cited by 12
Rey, F., Messa, L., Maghraby, E., Casili, G., Ottolenghi, S., Barzaghini, B., Raimondi, M. T., Cereda, C., Cuzzocrea, S., Zuccotti, G., et al. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0046 · Cited by 11
Wang, B., Chen, J., Wang, S., Chen, L., Zhang, X., Zhou, T., Zhong, J., Zhang, C., He, Y., Zuo, Y., et al. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2206171 · Cited by 11
Amylin and Secretases in the Pathology and Treatment of Alzheimer’s Disease
Singh, S. P., Yang, F., Sivils, A., Cegielski, V., & Chu, X. (2022) · Biomolecules · doi:10.3390/biom12070996 · Cited by 11
Sanches, K., Prypoten, V., Chandy, K. G., Chalmers, D. K., & Norton, R. S. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01237 · Cited by 11
Mitral cells and the glucagon‐like peptide 1 receptor: The sweet smell of success?
Bagnoli, E., & FitzGerald, U. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14115 · Cited by 10
Hou, J., Hess, J., Zhang, C., van Rooij, J., Hearn, G. C., Fan, C. C., Faraone, S. V., Fennema‐Notestine, C., Lin, S., Escott‐Price, V., et al. (2024) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.33019 · Cited by 11
A Fluorescent Peptide Toxin for Selective Visualization of the Voltage-Gated Potassium Channel KV1.3
Wai, D. C. C., Naseem, M. U., Mocsár, G., Reddiar, S. B., Pan, Y., Csóti, A., Hajdú, P., Nowell, C. J., Nicolazzo, J. A., Panyi, G., et al. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00436 · Cited by 9
Association between gene expression and altered resting-state functional networks in type 2 diabetes
Zhang, Y., Du, X., Qin, W., Fu, Y., Wang, Z., & Zhang, Q. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1290231 · Cited by 8
Unraveling neuroprotection with Kv1.3 potassium channel blockade by a scorpion venom peptide
Beraldo-Neto, E., Ferreira, V. F., Vigerelli, H., Beraldo, K. R. F., Juliano, M. A., Nencioni, A. L. A., & Pimenta, D. C. (2024) · Scientific Reports · doi:10.1038/s41598-024-79152-1 · Cited by 8
Identification of Novel Kv1.3 Channel-Interacting Proteins Using Proximity Labelling in T-Cells
Kour, D., Bowen, C. A., Srivastava, U., Nguyen, H. M., Kumari, R., Kumar, P., Brandelli, A. D., Bitarafan, S., Tobin, B. R., Wood, L. B., et al. (2025) · Cellular Physiology and Biochemistry · doi:10.33594/000000823 · Cited by 8
Self-citationShK toxin: history, structure and therapeutic applications for autoimmune diseases
Chang, S. C., Bajaj, S., & Chandy, K. G. (2018) · WikiJournal of Science · doi:10.15347/wjs/2018.003 · Cited by 8
Izadi, F., & Soheilifar, M. H. (2018) · PubMed Central · Cited by 8
Sani, N. F. A., Hamzah, A. I. Z. A., Bakar, Z. H. A., Yusof, Y. A. M., Makpol, S., Ngah, W. Z. W., & Damanhuri, H. A. (2021) · Cells · doi:10.3390/cells10071611 · Cited by 6
Du, J., Xu, S., & Zhu, W. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241309098 · Cited by 5
Perumal, N., Yurugi, H., Dahm, K., Rajalingam, K., Grus, F. H., Pfeiffer, N., & Manicam, C. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.128464 · Cited by 4
Kv1.3 In Microglia: Neuroinflammatory Determinant and Promising Pharmaceutical Target
Felipe, A. (2018) · Journal of Neurology and Neuromedicine · doi:10.29245/2572.942x/2018/4.1191 · Cited by 4
Shalaby, H. N., Nawwar, D. A., Kamel, A. S. E. D., & El-Said, Y. A. M. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177647 · Cited by 3
Ye, F., Li, Q., Huang, L., & Liao, N. (2025) · Drug Delivery · doi:10.1080/10717544.2025.2490269 · Cited by 3
Non-conducting functions of potassium channels in cancer and neurological disease
Sesti, F., Bortolami, A., & Forzisi, E. (2023) · Current topics in membranes · doi:10.1016/bs.ctm.2023.09.007 · Cited by 3
Wang, Y., Wang, Q., Li, R., Yu, Y., Feng, S., Wu, W., & Ren, S. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107185 · Cited by 2
Zhou, Y., Zhou, F., & Li, H. X. (2025) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-164601 · Cited by 2
SARS-CoV-2 Spike Protein S1 Subunit Induces Neuroinflammation Via Microglial Kv1.3 Channel
Lee, H.-Y., Lee, Y., Jo, S., & Choi, S. (2026) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2026.100716 · Cited by 2
Kour, D., Srivastava, U., Eddy, T., Mehta, L., Kumari, R., & Rangaraju, S. (2026) · Current Opinion in Immunology · doi:10.1016/j.coi.2026.102757 · Cited by 2
Self-citation
Metadata
- Authors
- Rangaraju, S., Gearing, M., Jin, L.-W., & Levey, A.
- Affiliations
- Emory University (US)
- University of California, Davis (US)
- Corresponding author
- Rangaraju, Srikant
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2015-02-06
- Volume
- 44
- Issue
- 3
- Pages
- 797-808
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC4402159
- OpenAlex
- W1718126001
- Cited by
- 137
- References
- 47
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 10 · 2023: 10 · 2022: 16 · 2021: 22 · 2020: 15 · 2019: 6 · 2018: 15 · 2017: 11 · 2016: 5 · 2015: 4
- FWCI
- 6.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- American Brain Foundation
- Emory University (P50AG025688, AG025688)
- Alzheimer's Disease Research Center, Emory University (P50 AG025688, AG025688)
- National Institute on Aging (P50AG025688)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- Kv1.3 potassium channel, microglia
- MeSH terms
- Aged, Alzheimer Disease, Brain, Calcium-Binding Proteins, DNA-Binding Proteins, Female, Glial Fibrillary Acidic Protein, Humans, Male, Microfilament Proteins, Tubulin, Amyloid beta-Peptides, Microglia, Kv1.3 Potassium Channel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.